A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia
CEO: Ben Chung-Bin Hwang. Company website
Profusa, Inc. Common Stock (PFSA) trades at $2.27, up 24.04% on the day, as of Sep 20, 2026 14:59 UTC.
Profusa, Inc. Common Stock has a market capitalisation of $1.26M, calculated from the live PFSA share price and shares outstanding.
PFSA has no meaningful price-to-earnings ratio: Profusa, Inc. Common Stock lost $174.21 per share over the last twelve months, and a P/E is only defined on positive earnings.
Profusa, Inc. Common Stock generated revenue of $0.00 over the trailing twelve months.
PFSA has traded between $0.36 and $28.32 over the past 52 weeks, and the last price is 92.0% below that high.
Yes. Profusa, Inc. Common Stock keeps 0.00% of revenue as net income over the trailing twelve months.
Profusa, Inc. Common Stock is classified under the Healthcare sector and the Medical - Equipment & Services industry, and is domiciled in US .
Ben Chung-Bin Hwang is the chief executive of Profusa, Inc. Common Stock, which employs 2 people.
QFI Terminal shows PFSA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PFSA in Terminal See plans